Payment overview · 2025
General Payments
$186.97
8 reported records · 8 companies
Healthcare provider profile · identity verified
David M Nadeau, MD
Allopathic & Osteopathic Physicians|Family Medicine · MUSKEGON, MI · NPI 1750357232
Verified facts
What the public records show
CMS Open Payments records show David M Nadeau, MD received $186.97 in general payments during 2025 across 8 reported records.
Axsome Therapeutics, Inc. accounted for 16.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Nurtec Odt, Ozempic.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 137 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 145 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 41 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nurtec Odt by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $30.20 | 16.1% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $26.87 | 14.4% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.93 | 13.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $23.70 | 12.7% | 1 | 2025 |
| Vanda Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $22.16 | 11.8% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $20.12 | 10.8% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $19.56 | 10.5% | 1 | 2025 |
| Supernus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.43 | 9.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $186.97 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $30.20 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.87 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $25.93 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $23.70 | 1 | 2025 |
Source payment records
|
|||||
| FANAPT Normalized: fanapt |
Drug | Vanda Pharmaceuticals Inc. | $22.16 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $20.12 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $19.56 | 1 | 2025 |
Source payment records
|
|||||
| Qelbree Normalized: qelbree |
Drug | Supernus Pharmaceuticals, Inc. | $18.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 146 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 145 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 41 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
137 | 33 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
145 | 22 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
43 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
41 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
54 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
146 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 564 | 171 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 470 | 84 |
| Levothyroxine Sodium | Levothyroxine Sodium | 457 | 129 |
| Metoprolol Succinate | Metoprolol Succinate | 356 | 120 |
| Lisinopril | Lisinopril | 309 | 102 |
| Amlodipine Besylate | Amlodipine Besylate | 306 | 99 |
| Losartan Potassium | Losartan Potassium | 305 | 90 |
| Gabapentin | Gabapentin | 304 | 87 |
| Omeprazole | Omeprazole | 290 | 82 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 275 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 224 | 66 |
| Metformin Hcl | Metformin Hcl | 222 | 61 |
| Montelukast Sodium | Montelukast Sodium | 211 | 54 |
| Pantoprazole Sodium | Pantoprazole Sodium | 208 | 56 |
| Metoprolol Tartrate | Metoprolol Tartrate | 201 | 53 |
| Tramadol Hcl | Tramadol Hcl | 196 | 50 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 190 | 70 |
| Furosemide | Furosemide | 185 | 55 |
| Alprazolam | Alprazolam | 183 | 47 |
| Duloxetine Hcl | Duloxetine Hcl | 171 | 42 |
| Allopurinol | Allopurinol | 166 | 44 |
| Hydrochlorothiazide | Hydrochlorothiazide | 164 | 55 |
| Simvastatin | Simvastatin | 158 | 45 |
| Pregabalin | Pregabalin | 152 | 32 |
| Metformin Hcl Er | Metformin Hcl | 148 | 47 |
| Eliquis | Apixaban | 146 | 38 |
| Glimepiride | Glimepiride | 146 | 36 |
| Mounjaro | Tirzepatide | 145 | 22 |
| Potassium Chloride | Potassium Chloride | 143 | 41 |
| Jardiance | Empagliflozin | 137 | 33 |
| Trazodone Hcl | Trazodone Hcl | 134 | 37 |
| Pravastatin Sodium | Pravastatin Sodium | 131 | 38 |
| Ezetimibe | Ezetimibe | 115 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 108 | 24 |
| Clopidogrel | Clopidogrel Bisulfate | 100 | 29 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 23 |
| Farxiga | Dapagliflozin Propanediol | 93 | 16 |
| Bupropion Xl | Bupropion Hcl | 91 | 22 |
| Cephalexin | Cephalexin | 91 | 47 |
| Meloxicam | Meloxicam | 91 | 31 |
| Carvedilol | Carvedilol | 88 | 27 |
| Pioglitazone Hcl | Pioglitazone Hcl | 85 | 27 |
| Alendronate Sodium | Alendronate Sodium | 81 | 25 |
| Famotidine | Famotidine | 81 | 28 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 81 | 25 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 81 | 21 |
| Sertraline Hcl | Sertraline Hcl | 78 | 25 |
| Spironolactone | Spironolactone | 78 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 78 | 11 |
| Buspirone Hcl | Buspirone Hcl | 76 | 20 |
| Prednisone | Prednisone | 74 | 35 |
| Atenolol | Atenolol | 73 | 24 |
| Citalopram Hbr | Citalopram Hydrobromide | 72 | 24 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 72 | 23 |
| Lovastatin | Lovastatin | 72 | 19 |
| Mirtazapine | Mirtazapine | 71 | 17 |
| Clonazepam | Clonazepam | 69 | 18 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 67 | 19 |
| Tizanidine Hcl | Tizanidine Hcl | 65 | 25 |
| Fluticasone Propionate | Fluticasone Propionate | 64 | 30 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 61 | 22 |
| Azithromycin | Azithromycin | 59 | 43 |
| Celecoxib | Celecoxib | 56 | 25 |
| Donepezil Hcl | Donepezil Hcl | 56 | 14 |
| Ibuprofen | Ibuprofen | 55 | 12 |
| Finasteride | Finasteride | 54 | 17 |
| Rybelsus | Semaglutide | 54 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 53 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 53 | 15 |
| Fenofibrate | Fenofibrate Nanocrystallized | 52 | 13 |
| Methadone Hcl | Methadone Hcl | 52 | suppressed |
| Torsemide | Torsemide | 52 | 17 |
| Aripiprazole | Aripiprazole | 51 | 14 |
| Ondansetron Odt | Ondansetron | 51 | 17 |
| Lamotrigine | Lamotrigine | 46 | suppressed |
| Lorazepam | Lorazepam | 46 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 44 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 44 | 35 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 44 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 43 | 14 |
| Trulicity | Dulaglutide | 43 | 12 |
| Ozempic | Semaglutide | 41 | 14 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 40 | 17 |
| Xarelto | Rivaroxaban | 40 | 11 |
| Baclofen | Baclofen | 39 | 15 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 39 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 38 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 38 | suppressed |
| Estradiol | Estradiol | 37 | 12 |
| Gemfibrozil | Gemfibrozil | 36 | suppressed |
| Ketoconazole | Ketoconazole | 36 | 20 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 36 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 36 | 18 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 35 | 20 |
| Solifenacin Succinate | Solifenacin Succinate | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 35 | 26 |
| Bupropion Hcl Sr | Bupropion Hcl | 34 | suppressed |
| Diazepam | Diazepam | 34 | 12 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 34 | 11 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 33 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 33 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 32 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 19 |
| Bumetanide | Bumetanide | 31 | suppressed |
| Colchicine | Colchicine | 31 | suppressed |
| Fluconazole | Fluconazole | 31 | 16 |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 30 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 28 | 27 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 28 | suppressed |
| Januvia | Sitagliptin Phosphate | 28 | suppressed |
| Fenofibrate | Fenofibrate | 27 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 27 | suppressed |
| Myrbetriq | Mirabegron | 27 | suppressed |
| Nitroglycerin | Nitroglycerin | 27 | 23 |
| Synthroid | Levothyroxine Sodium | 27 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 27 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 27 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 25 | suppressed |
| Linzess | Linaclotide | 25 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 25 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 25 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 25 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 24 | 21 |
| Enalapril Maleate | Enalapril Maleate | 24 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 24 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 24 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 23 | suppressed |
| Amoxicillin | Amoxicillin | 22 | 17 |
| Cefdinir | Cefdinir | 22 | 17 |
| Digoxin | Digoxin | 22 | suppressed |
| Methylprednisolone | Methylprednisolone | 22 | 18 |
| Risperidone | Risperidone | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 21 | suppressed |
| Memantine Hcl | Memantine Hcl | 21 | suppressed |
| Olanzapine | Olanzapine | 21 | suppressed |
| Chlorthalidone | Chlorthalidone | 20 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 19 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 19 | suppressed |
| Invokana | Canagliflozin | 19 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Nifedipine Er | Nifedipine | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Victoza 3-Pak | Liraglutide | 18 | suppressed |
| Acyclovir | Acyclovir | 17 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Novolog Flexpen | Insulin Aspart | 17 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Sucralfate | Sucralfate | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Fentanyl | Fentanyl | 16 | suppressed |
| Naproxen | Naproxen | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Valacyclovir | Valacyclovir Hcl | 16 | 11 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 16 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 15 | suppressed |
| Jantoven | Warfarin Sodium | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Constulose | Lactulose | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Telmisartan | Telmisartan | 14 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Valsartan | Valsartan | 14 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Buprenorphine | Buprenorphine | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Humalog | Insulin Lispro | 13 | suppressed |
| Indapamide | Indapamide | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Calcitonin-Salmon | Calcitonin,salmon,synthetic | 12 | suppressed |
| Glipizide Er | Glipizide | 12 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 12 | suppressed |
| Progesterone | Progesterone, Micronized | 12 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 11 | suppressed |
| Brilinta | Ticagrelor | 11 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 11 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 11 | suppressed |
| Gemtesa | Vibegron | 11 | suppressed |
| Glycopyrrolate | Glycopyrrolate | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Liraglutide | Liraglutide | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Norethindrone | Norethindrone | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 11 | suppressed |
| Temazepam | Temazepam | 11 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $186.97 · 8 records | Axsome Therapeutics, Inc. | Auvelity, CAPVAXIVE, Cologuard Collection Kit, ELIQUIS, FANAPT, GARDASIL 9, MOUNJARO, NURTEC ODT, Ozempic, Qelbree, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error